|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Asia Pacific in vitro diagnostics market is projected to register a CAGR of about 5.68% during the forecast period, with a revenue of approximately USD 17,812.62 million in 2020, and it is expected to reach USD 25,744.58 million by 2026.
The COVID-19 pandemic has turned a spotlight on the in vitro diagnostics industry in Asia, with the rapid development of diagnostics, fast-tracked regulatory clearances, and ramped-up distribution in various regions to help curb the spread of the virus.
In vitro diagnostics (IVDs) have always been essential in the detection of infectious diseases. Currently, many molecular assays and immunoassays are in place to detect COVID-19. However, quality diagnostics that provide faster and accurate test results are the need of the hour.
Asia Pacific is a region with growing middle-class populations, stabilizing economies, increasingly urban populations, and supportive governments. It is showing a major shift in the private healthcare sector, which is a supporting factor for the market.
The prevalence of various chronic diseases significantly increased in Asia Pacific countries over the past decade. The threat from these diseases to public health has increased significantly, which has resulted in the growing adoption of new diagnostic techniques, including point-of-care testing.
In Asia Pacific countries, like India, Japan, and China, there has been an increase in the demand for IVD devices on account of the aging populations, escalating prevalence rates of lifestyle diseases, and growth in the healthcare sectors. Additionally, the market is impacted by establishing standalone centers, independent diagnostics chains, and academic institutes.
Based on end users, currently, hospital-based centers form the leading market segment. In recent years, there has been a steep increase in the number of public-private partnership (PPP) opportunities in Asia Pacific countries. This factor is expected to drive the ongoing smart hospital projects, contributing to the growth of the overall market.
Moreover, many governments are taking several initiatives with respect to in vitro diagnostics, which are also fueling the overall market growth. The Indian government is taking positive steps to boost the capacities of the domestic IVD sector. The formulation of the Medical Devices Rule (2017), which came into effect from January 1, 2018, was a key measure that directs investment inflows into the sector and reduces the production cost of devices. Thus, these benefits can be passed on to end users.
Scope of the Report
As per the scope of the report, in vitro diagnostics involve medical devices and consumables that are utilized to perform in-vitro tests on various biological samples. They are used for diagnosing various medical conditions, such as diabetes and cancer. The Asia Pacific in vitro diagnostics market is segmented by test type (clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, and other test types), product (instruments, reagents, and other products), usability (disposable IVD Devices and reusable IVD devices), application (infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications), end user (diagnostic laboratories, hospitals and clinics, and other end users), and geography (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific). The report offers values (in USD million) for the above segments.
|By Test Type|
|Other Test Types|
|Disposable IVD Devices|
|Reusable IVD Devices|
|By End User|
|Hospitals and Clinics|
|Other End Users|
|Rest of Asia-Pacific|
Key Market Trends
Clinical Chemistry Segment is Expected to Record the Highest Growth in the Forecast Period
Clinical chemistry is a combination of analytics, instrumentation, information technology, and the management of workflow. Technological advancements have led to increased automation of detection techniques pertaining to biologically important ions (salts and minerals), small organic molecules, and large molecules, such as enzymes, transport proteins, and lipoproteins, among others.
Analyzers are instruments that analyze samples, such as blood, serum, and urine. Clinical chemistry analyzers are witnessing high growth, owing to the development of technologies employed in these instruments. For instance, in July 2019, in India, Trivitron Healthcare launched a clinical chemistry analyzer, Nanolab 200, a fully automated, compact, bench-top clinical chemistry analyzer, with a throughput of 200 tests per hour. This system includes multi-functional sample and reagent probes, with collision protection and liquid level detection technology. Furthermore, the increasing prevalence of target diseases, like liver diseases, thyroid functions, cancers, etc., boosts the segment’s growth.
To understand key trends, Download Sample Report
The Asia Pacific in vitro diagnostics market is highly competitive and consists of several major players. In terms of market share, a few major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lower prices. Some of the major players in the region are Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific, and F Hoffmann-La Roche Ltd.
- In May 2020, bioMérieux received the CE marking for VIDAS anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 that causes COVID-19.
- In January 2020, Beckman Coulter launched DxH560 AL, a tabletop analyzer geared to reduce the time and resource constraints faced by small to mid-sized laboratories.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies in In-vitro Diagnostic Products
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations Regarding Product Approvals
4.3.2 Cumbersome Reimbursement Procedures
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.5 Other Test Types
5.2 By Product
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Diseases
5.4.5 Autoimmune Diseases
5.4.7 Other Applications
5.5 By End User
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals and Clinics
5.5.3 Other End Users
5.6 By Geography
5.6.5 South Korea
5.6.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 bioMérieux SA
6.1.2 Danaher (Beckman Coulter)
6.1.3 F Hoffmann-La Roche Ltd
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthineers
6.1.11 Thermo Fischer Scientific Inc.
6.1.12 Qiagen NV
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Asia Pacific In Vitro Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of Asia Pacific In Vitro Diagnostics Market?
The Asia Pacific In Vitro Diagnostics Market is growing at a CAGR of 5.68% over the next 5 years.
What is Asia Pacific In Vitro Diagnostics Market size in 2018?
The Asia Pacific In Vitro Diagnostics Market is valued at 17812 Million USD in 2018.
What is Asia Pacific In Vitro Diagnostics Market size in 2026?
The Asia Pacific In Vitro Diagnostics Market is valued at 25744 Million USD in 2026.
Which region has highest growth rate in Asia Pacific In Vitro Diagnostics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Asia Pacific In Vitro Diagnostics Market?
North America holds highest share in 2020.
Who are the key players in Asia Pacific In Vitro Diagnostics Market?
Abbott Laboratories, Siemens Healthineers AG , bioMérieux SA , Thermo Fisher Scientific, F Hoffmann-La Roche Ltd are the major companies operating in Asia Pacific In Vitro Diagnostics Market.